Dynavax Technologies

Dynavax Technologies

  • Founded in 1996
  • 201-500 Employees
  • $200M Post-IPO Debt on 2021-05

Careers at Dynavax Technologies


About Dynavax Technologies

Dynavax Technologies is a commercial-stage biopharmaceutical company focused on developing and commercializing novel vaccines to combat infectious diseases. The company utilizes proven and innovative adjuvant technology, such as its CpG 1018® adjuvant, to enhance the effectiveness of vaccines, including its HEPLISAV-B® product. With a commitment to making a global impact on public health, Dynavax actively engages in clinical trials and values driven team collaborations to advance its pipeline of vaccine solutions.